TIL Therapy Promising in Uveal Melanoma, Tool Predicts Responders
Source: CureToday, April 2024
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
Researchers have found a new strategy that may help uveal melanoma respond to conventional immunotherapy. The adoptive therapy, which involves growing immune T cells outside of the patient’s body and then reinfusing them, was recently explained in Nature Communications.
“The dogma was that uveal melanoma is a ‘cold’ cancer, meaning that T cells can’t get into these tumors,” senior author Dr. Udai Kammula, associate professor of surgery at Pitt and director of the Solid Tumor Cell Therapy Program at UPMC Hillman Cancer Center, said in a press release.